Vamorolone and the LIONHEART & VISION-DMD Data

This sponsored multi-part series examines the evolving role of vamorolone in the care of patients with Duchenne muscular dystrophy (DMD). Through conversations with clinical experts across specialties, the series explores the clinical data, safety considerations, and real-world positioning of vamorolone within modern DMD treatment strategies. Each episode offers focused insight into how this therapy may influence both short- and long-term care decisions.

In this episode, Migvis Monduy, MD, pediatric neurologist and medical director of the Cerebral Palsy and Neuromotor Center at Nicklaus Children’s Hospital, discusses how findings from the LIONHEART and VISION-DMD studies contribute to the clinical understanding of vamorolone. Moving beyond efficacy alone, the conversation centers on how mechanistic and biomarker data may help distinguish vamorolone from traditional corticosteroids.

In this segment, Monduy explains what mineralocorticoid receptor activity means in practical terms, how serum and biomarker findings reinforce vamorolone’s differentiated profile, and why these data may have implications for long-term systemic effects. The discussion also explores the potential downstream relevance of these findings, including what they could suggest for cardiovascular health and durability over time.